Ultivue, Paige partner to advance AI products

By LabPulse.com staff writers

April 8, 2022 -- Boston-based biomarker assay developer Ultivue and artificial intelligence (AI) software developer Paige have established a collaborative agreement to develop and market AI-powered spatial immunophenotype capabilities for pharmaceutical and research customers.

Efforts will initially focus on the development of AI to enable improved understanding of the tumor microenvironment and support the interpretation of Ultivue's novel multiplex immunofluorescence (mIF) immuno-oncology biomarker panels, the companies said.

Paige unveils breast lymph node software at USCAP 2022
Artificial intelligence-based software developer Paige unveiled its breast lymph node application at this week's United States and Canadian Academy of...
Paige links with Flagship on biomarker analysis tools
Pathology artificial intelligence software developer Paige has inked a partnership with Flagship Biosciences that makes Flagship's diagnostics software...
Paige partners with Mindpeak for AI breast cancer software
Paige and Mindpeak have announced a distribution partnership that will enable pathologists to use Mindpeak's BreastIHC artificial intelligence (AI) software...
Paige appoints new executives
Artificial intelligence software developer Paige announced that it has appointed new executive leaders, including Andy Moye, PhD, as CEO and Jill Stefanelli,...
Paige AI software gets U.K. medtech innovation evaluation
The U.K.'s National Institute for Health and Care Excellence (NICE) has published a Medtech Innovation Briefing (MIB) on Paige's Paige Prostate artificial...

Copyright © 2022 LabPulse.com

Last Updated 4/8/2022 7:13:37 AM